In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates.

In this study, we evaluated the in vitro activity of KBP-7072 and comparator agents by CLSI M07 (2018) broth microdilution against 531 recent geographically diverse and/or molecularly characterized Acinetobacter baumannii-calcoaceticus species complex (A. baumannii) isolates from the United States, Europe, Asia-Pacific (excluding China), and Latin America. A. baumannii isolates included carbapenem-resistant, colistin-resistant, tetracycline-resistant, and extended-spectrum β-lactamase (ESBL)- and metallo-β-lactamase (MBL)-producing isolates. Overall, KBP-7072 (MIC50/90, 0.25/1 mg/L) was comparable in activity to colistin (92.8%/92.8% S [CLSI/EUCAST]) against A. baumannii isolates, inhibiting 99.2% of isolates at ≤2 mg/L and 97.6% of isolates at ≤1 mg/L. KBP-7072 was equally active against A. baumannii isolates including carbapenem-resistant, colistin-resistant and tetracycline-resistant isolates, regardless of geographic location, and maintained activity against ESBL- and MBL-producing isolates. KBP-7072 outperformed comparator agents, including ceftazidime (40.3%S [CLSI]), gentamicin (48.2%/48.2%S [CLSI/EUCAST]), levofloxacin (39.5%/37.9%S [CLSI/EUCAST]), meropenem (42.0%/42.0%S [CLSI/EUCAST]), piperacillin-tazobactam (33.3%S [CLSI]) and all tetracycline-class comparator agents that include doxycycline (67.3%S, [CLSI], minocycline (73.8%S [CLSI]), tetracycline (37.2%S [CLSI]), and tigecycline (79.5% inhibited by ≤2 mg/L). The potent in vitro activity of KBP-7072 agai...

Source: Antimicrobial Agents and Chemotherapy - February 17, 2020 Category: Microbiology Authors: Huband MD, Mendes RE, Pfaller MA, Lindley JM, Strand GJ, Benn VJ, Zhang J, Li L, Zhang M, Tan X, Liu Q, Flamm RK Tags: Antimicrob Agents Chemother Source Type: research